NeuroGenesis Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $6.66M

  • Investors
  • 6

NeuroGenesis General Information

Description

Developer of cell therapies designed to treat neurodegenerative diseases. The company includes features such as proprietary methods for selecting and modifying autologous stem cells, mechanisms for sustained delivery of therapeutic proteins into affected neural tissues, integration of clinical trial protocols and data, and cell delivery procedures tailored to central nervous system targets, enabling researchers and clinicians in the biotechnology and medical research market to pursue potential treatment avenues for progressive neurological diseases with a focus on repairing and mitigating degeneration rather than solely managing symptoms.

Contact Information

Website
www.neurogenesis-cell.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 410 White Spruce Boulevard
  • Rochester, NY 14623
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences
Corporate Office
  • 410 White Spruce Boulevard
  • Rochester, NY 14623
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroGenesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC (Series A) 11-Mar-2022 $6.66M Completed Clinical Trials - Phase 2
To view NeuroGenesis’s complete valuation and funding history, request access »

NeuroGenesis Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

NeuroGenesis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4232565-A1 Mesenchymal stem cells and their culture Pending 26-Oct-2020
EP-4232565-A4 Mesenchymal stem cells and their culture Pending 26-Oct-2020
US-20230365937-A1 Mesenchymal stem cells and their culture Pending 26-Oct-2020
WO-2022091086-A1 Mesenchymal stem cells and their culture Inactive 26-Oct-2020 C12N5/0663

NeuroGenesis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuroGenesis Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Excell Partners Venture Capital Minority
Hadasit Venture Capital Minority
Morgan Stanley Investment Bank Minority
New York State Office of Community Renewal Government Minority
New York Ventures Corporate Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

NeuroGenesis FAQs

  • When was NeuroGenesis founded?

    NeuroGenesis was founded in 2005.

  • Where is NeuroGenesis headquartered?

    NeuroGenesis is headquartered in Rochester, NY.

  • What is the size of NeuroGenesis?

    NeuroGenesis has 12 total employees.

  • What industry is NeuroGenesis in?

    NeuroGenesis’s primary industry is Drug Discovery.

  • Is NeuroGenesis a private or public company?

    NeuroGenesis is a Private company.

  • What is NeuroGenesis’s current revenue?

    The current revenue for NeuroGenesis is .

  • How much funding has NeuroGenesis raised over time?

    NeuroGenesis has raised $6.66M.

  • Who are NeuroGenesis’s investors?

    Excell Partners, Hadasit, Morgan Stanley, New York State Office of Community Renewal, and New York Ventures are 5 of 6 investors who have invested in NeuroGenesis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process